Full-Time

Senior Specialist

Global Regulatory Operations, Systems Support

Updated on 7/3/2025

Viatris

Viatris

10,001+ employees

Global healthcare company providing medicines access

No salary listed

Senior

Remote in USA

Remote

Telecommuting permitted from anywhere within the United States.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Python
JavaScript
Bootstrap
Pandas
HTML/CSS
Django
Requirements
  • Bachelor’s degree or foreign equivalent in Computer Science, Information Technology, Computer Engineering, or a related field
  • 3 years of experience in the position offered or related
  • 3 years of experience with working with relational database systems and object-oriented programming languages including Django Web Development Framework, Microsoft SQL Server, Python, and related packages
  • Using business intelligence tools including Django Web Development Framework, Python and related packages for processing, analyzing, and aggregating complex data sets related to regulatory affairs within the pharmaceutical industry
  • Applying knowledge of applicable federal and state regulatory laws, Occupational Safety and Health Administration (OSHA) guidelines, health authority regulations, and departmental processes within the pharmaceutical industry
  • Performing web application development including Django Web Development Framework, Python and related packages (pandas, beautiful soup), JavaScript, AJAX, Bootstrap, CSS, HTML, and Datatables.
Responsibilities
  • Work with the Global Regulatory Operational Informatics group in the creation of business intelligence tools for processing, analyzing, and aggregating complex data sets
  • Produce reports and metrics for consumption by a variety of business units, while ensuring compliance with all applicable Standard Operating Procedures (SOP), federal and state laws, Occupational Safety and Health Administration (OSHA) guidelines, health authority regulations, and departmental processes
  • Compare and integrate data sets from a variety of systems and spreadsheets to present report findings and future operation strategies
  • Design and develop business intelligence tools to make the consumption of information easier for regulatory users across Mylan’s global platforms
  • Evaluate submission tracking questions, metrics, reports and other system-related information
  • Analyze, data mine and model historical submission activities to track trends, identify atypical behavior, predict future approval dates, and provide a baseline for operating metrics
  • Assist with system compliance checks across Mylan’s various regulatory systems
  • Identify process gaps, best practices, and internal opportunities for increased efficiencies and standardization, particularly around automation via the use of technology
  • Analyze and compare data in the Global Application Tracking System including applications, supplements, amendments, patents and the chronology and transaction history against other relevant data sources
  • Collaborate with Regulatory Affairs personnel to socialize proposed changes and ensure input from all stakeholders
  • Perform research on required topics to help understand the regulatory requirements related to assigned projects.

Viatris provides a wide range of healthcare solutions by combining generic and brand-name medications to meet global health needs. The company operates a global supply chain that allows it to deliver high-quality medicines to patients in various locations, ensuring access to essential treatments. Viatris's extensive portfolio includes medications for both acute and chronic conditions, addressing health challenges throughout different stages of life. Unlike many competitors, Viatris focuses on bridging the gap between generics and brands, which enables them to reach a broader audience. The company's goal is to empower individuals worldwide to lead healthier lives by providing access to necessary medications.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Simplify Jobs

Simplify's Take

What believers are saying

  • Viatris' licensing deal for sotagliflozin expands its cardiovascular drug market presence.
  • Positive Phase 2 results for cenerimod highlight potential in the lupus treatment market.
  • Resolution of DOJ's antitrust investigation boosts investor confidence and stock performance.

What critics are saying

  • Increased biosimilar competition from Amgen and Pfizer may pressure Viatris' margins.
  • Global drug price reductions could impact Viatris' generic drug revenue.
  • Operational challenges may arise from integrating Biocon's acquired assets.

What makes Viatris unique

  • Viatris bridges the gap between generics and brands, offering a unique healthcare approach.
  • The company has a vast global supply chain reaching approximately 1 billion patients annually.
  • Viatris' diverse portfolio includes biosimilars, generics, and innovative drugs like sotagliflozin.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Company News

The Indian Express
Jun 24th, 2025
Biocon's $3.3B Viatris Acquisition Impact

Biocon's acquisition of Viatris for $3.3 billion marks a potential turning point for the company, which has seen muted growth. Despite revenue growth, concerns about debt, equity dilution, and valuation persist. Biocon's business now includes biosimilars, contract research, and generics. The company plans to raise ₹4,500 crore through a Qualified Institutional Placement to reduce its ₹17,756 crore debt. A potential merger with Biocon Biologics Ltd could unlock further value.

PharmiWeb
May 7th, 2025
Viatris Announces Quarterly Dividend

PITTSBURGH, May 7, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on May 5, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on June 16, 2025, to shareholders of record as of the close of business on May 23, 2025.About ViatrisViatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris

PR Newswire
Mar 28th, 2025
Viatris To Report First Quarter 2025 Financial Results On May 8, 2025

PITTSBURGH, March 28, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will report first quarter 2025 financial results on Thursday, May 8, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 844.308.3344 or 412.317.1896 for international callers. A replay of the webcast also will be available on the website.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally

PR Newswire
Mar 5th, 2025
Viatris To Present At The Barclays 27Th Annual Global Healthcare Conference

PITTSBURGH, March 5, 2025 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, will present at the Barclays 27th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, March 11, 2025. The company's fireside chat will begin at 2 p.m. ET.A live webcast of the event at can be found at investor.viatris.com. An archived version of the presentation will be available following the live event and can be accessed at the same location for a limited time.About ViatrisViatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally